Brief report: Effectiveness of combination antiretroviral therapy on survival and opportunistic infections in a developing world setting: An observational cohort study

Journal of Acquired Immune Deficiency Syndromes

Volumn 44, Issue 4, 2007, Pages 451-455

  Corey, Daniel M ^a,d,f   Kim, Hyung Woo ^a,e   Salazar, Raul ^b   Illescas, Ricardo ^b   Villena, Juan ^b   Gutierrez, Luis ^b   Sanchez, Jorge ^c   Tabet, Stephen R ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b HOSPITAL NACIONAL GUILLERMO ALMENARA IRIGOYEN   (Peru)

^c ASOCIACIÓN CIVIL IMPACTA SALUD Y EDUCACIÓN   (Peru)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Antiretroviral therapy; CD4 counts; Opportunistic infection

Indexed keywords

DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DEVELOPING COUNTRY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PERU; PRIORITY JOURNAL; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HOSPITAL INFORMATION SYSTEMS; HUMANS; MALE; MIDDLE AGED; PERU; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34147100114     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31802f8512     Document Type: Article

References (21)

1. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129.
2. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med. 2003;138:620-626.
3. Attaran A, Sachs J. Defining and refining international donor support for combating the AIDS pandemic. Lancet. 2001;357:57-61.
4. Kitahata MM, Koepsell TD, Deyo RA, et al. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med. 1996;334:701-706.
5. Dybul M, Fauci AS, Bartlett JG, et al. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med. 2002;137:381-433.
6. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002; updated recommendations of the International AIDS Society-USA Panel. JAMA. 2002;288:222-235.
7. Hogan DR, Salomon JA. Prevention and treatment of human immunodeficiency virus/acquired immunodeficiency syndrome in resource-limited settings. Bull World Health Organ. 2005;83:135-143.
8. Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc. 1979;74:829-836.
9. Cleveland WS. LOWESS: a program for smoothing scatterplots by robust locally weighted regression. Am Stat. 1981;35:54.
10. Corey D, Kim HW, Salazar R, et al. The natural history of untreated HIV infection in Lima, Peru. Human Vaccines. 2005;1:160-164.
11. Deschamps MM, Fitzgerald DW, Pape JW, et al. HIV infection in Haiti: natural history and disease progression. AIDS. 2000;14:2515-2521.
12. Schneider M, Zwahlen M, Egger M. Natural history and mortality in HIV positive individuals living in resource poor settings: a literature review. UNAIDS Obligation HZ/03/463871, Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva (2005). Available at: http://www.epidem.org/publications.htm. Accessed November 2005.
13. Orrell C, Bangsberg DR, Badri M, et al. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS. 2003;17:1369-1375.
14. Sever P, Leger P, Charles M, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med. 2005;353:2325-2334.
15. Farmer P, Leandre F, Mukherjee J, et al. Community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy). Bull World Health Organ. 2001;79:1145-1151.
16. Tassie JM, Szumilin E, Calmy A, et al. Highly active antiretroviral therapy in resource-poor settings: the experience of Medecins Sans Frontieres. AIDS. 2003;17:1995-1997.
17. Weidle PJ, Malamba S, Mwebaze R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet. 2002;360:34-40.
18. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS. 2004;18:887-895.
19. Djomand G, Roels T, Ellerbrock T, et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote d'Ivoire. AIDS. 2003;17(Suppl 3):S5-S15.
20. Seyler C, Anglaret X, Dakoury-Dogbo N, et al. Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Cote d'Ivoire. Antivir Ther. 2003;8:385-393.
21. Laurent C, Diakhate N, Gueye NF, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS. 2002;16:1363-1370.